INTRODUCTION AND AIMS: Gastric mucosa-associated lymphoid tissue (MALT) lymphoma is closely associated with Helicobacter pylori (HP) infection. Our aim was to evaluate demographic, clinical and endoscopic characteristics of gastric MALT lymphoma patients, as well as to analyse response to treatment and factors that affect complete remission (CR) and relapse. We also assessed the long-term prognosis. METHODS: The study involved a retrospective evaluation of consecutive patients admitted with gastric MALT lymphoma (1993-2013). RESULTS: A total of 144 patients (76 men; mean age 56) were included. At stage EI, 94/103 patients (92%) received HP eradication and 78 (83%) achieved CR after a mean period of 7 months (2-63 months) and 67 (86%) remained in CR after a mean follow-up time of 105 months. HP infection status (p = 0.004) and lymphoma localisation to the antrum plus body (p = 0.016) were associated with higher and lower CR rates, respectively. Relapse occurred in 11/78 (14%) patients after a mean period of 21 months. The absence of HP re-infection (p = 0.038), the need of only one eradication regimen (p = 0.009) and antrum lymphomas (p = 0.031) correlated with lower relapse rates. At stage EII, HP eradication was performed in 17/24 patients but only five experienced CR (30%). Among 16 patients diagnosed at stage EIV, nine achieved CR after chemotherapy ± surgery and 3/7 without remission died due to disease progression. The 5- and 10-year overall disease free survival rates were 90.5% and 79.1%, respectively. CONCLUSIONS: Most patients were diagnosed at an early stage. Eradication therapy was highly effective in inducing complete remission. Long-term evaluation showed that the long-term prognosis was very favourable.
INTRODUCTION AND AIMS: Gastric mucosa-associated lymphoid tissue (MALT) lymphoma is closely associated with Helicobacter pylori (HP) infection. Our aim was to evaluate demographic, clinical and endoscopic characteristics of gastric MALT lymphomapatients, as well as to analyse response to treatment and factors that affect complete remission (CR) and relapse. We also assessed the long-term prognosis. METHODS: The study involved a retrospective evaluation of consecutive patients admitted with gastric MALT lymphoma (1993-2013). RESULTS: A total of 144 patients (76 men; mean age 56) were included. At stage EI, 94/103 patients (92%) received HP eradication and 78 (83%) achieved CR after a mean period of 7 months (2-63 months) and 67 (86%) remained in CR after a mean follow-up time of 105 months. HP infection status (p = 0.004) and lymphoma localisation to the antrum plus body (p = 0.016) were associated with higher and lower CR rates, respectively. Relapse occurred in 11/78 (14%) patients after a mean period of 21 months. The absence of HP re-infection (p = 0.038), the need of only one eradication regimen (p = 0.009) and antrum lymphomas (p = 0.031) correlated with lower relapse rates. At stage EII, HP eradication was performed in 17/24 patients but only five experienced CR (30%). Among 16 patients diagnosed at stage EIV, nine achieved CR after chemotherapy ± surgery and 3/7 without remission died due to disease progression. The 5- and 10-year overall disease free survival rates were 90.5% and 79.1%, respectively. CONCLUSIONS: Most patients were diagnosed at an early stage. Eradication therapy was highly effective in inducing complete remission. Long-term evaluation showed that the long-term prognosis was very favourable.
Authors: A Ruskoné-Fourmestraux; W Fischbach; B M P Aleman; H Boot; M Q Du; F Megraud; C Montalban; M Raderer; A Savio; A Wotherspoon Journal: Gut Date: 2011-02-11 Impact factor: 23.059
Authors: Hongxiang Liu; Hongtao Ye; Agnes Ruskone-Fourmestraux; Daphne De Jong; Stefano Pileri; Christian Thiede; Anne Lavergne; Henk Boot; Giancarlo Caletti; Thomas Wündisch; Thierry Molina; Babs G Taal; Sabattini Elena; Togliani Thomas; Pier Luigi Zinzani; Andreas Neubauer; Manfred Stolte; Rifat A Hamoudi; Ahmet Dogan; Peter G Isaacson; Ming-Qing Du Journal: Gastroenterology Date: 2002-05 Impact factor: 22.682
Authors: W Fischbach; M E Goebeler; A Ruskone-Fourmestraux; T Wündisch; A Neubauer; M Raderer; A Savio Journal: Gut Date: 2007-07-16 Impact factor: 23.059
Authors: Joon Sung Kim; Jun Chul Park; Jong Yeul Lee; Ji Yong Ahn; Sun Hyung Kang; Hyo-Joon Yang; Su Jin Kim; Moon Kyung Joo; Jae Myung Park Journal: Front Oncol Date: 2021-10-14 Impact factor: 6.244